This recombinant monoclonal antibody is developed as a research-grade biosimilar to NG-350A, targeting CD40, a crucial costimulatory protein member of the tumor necrosis factor receptor superfamily. CD40 is expressed on antigen-presenting cells, including B cells, dendritic cells, and macrophages, where it plays a pivotal role in regulating adaptive immune responses and inflammatory processes. Upon binding with its ligand CD154 (CD40L), CD40 initiates signaling cascades that promote B cell activation, antibody class switching, germinal center formation, and T cell priming. Dysregulation of CD40 signaling is implicated in various pathological conditions, including autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus, as well as B cell malignancies and solid tumors where it influences tumor microenvironment dynamics.
NG-350A is a genetically engineered oncolytic adenovirus that can infect tumor cells and express anti-CD40 agonist antibodies within them, strongly activating antigen-presenting cells such as dendritic cells, thereby initiating a systemic anti-tumor immune response. It is currently in clinical Phase I/II and is being evaluated for its safety, tolerability and preliminary efficacy in the treatment of advanced/metastatic epithelial cancer. This antibody is valuable for studies exploring immune cell interactions, inflammatory pathways, cancer immunology, and therapeutic target validation in preclinical models.
Email: support@cusabio.com
Distributors Worldwide